A Mayo Clinic study has suggested that the combination of biologic therapy with immune-suppressing drugs first instead of the drugs alone can be more than just beneficial to prompt remission from Crohn’s disease in a better way.
The study was published in the April 15, 2010 issue of the New England Journal of Medicine.
The study results are worthwhile enough to initiate a change in clinical practice, according to William Sandborn, M.D., gastroenterologist and vice chair of the Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester.
The therapy involving drug Sargramostim or Leukine could be helpful for managing disease activity and providing significant relief to patients afflicted with Crohn’s disease, which is a debilitating form of inflammatory bowel disease.
Dr. John F. Valentine, an associate professor of gastroenterology, Hepatology and nutrition at UF’s College of Medicine and the Malcom Randall Veterans Affairs Medical Center, was of the view that stimulation of the immune system is a better option of treatment than suppression of the immune system.
This finding was disclosed after a national multicenter study of the drug sargramostim was conducted by researchers from the Harvard Medical School, the University of Florida, and the Washington University School of Medicine and was reported in the May 26 issue of the New England Journal of Medicine.
Researchers from the University of Nottingham are launching a major clinical trial for evaluating the role of stem cells in rebooting the immune system and their efficacy in treating Crohn’s disease.
The researchers are evaluating if stem cells taken out from a patient’s own body could be used for providing effective remissions in the long run, an evaluation that could save tens of thousands of lives.
The Broad Medical Research Program of The Eli and Edythe Broad Foundation, a philanthropic organization based in California, funded this stem cell study into Crohn’s Disease at the University of Nottingham.
A therapy involving drug sargramostim, which is also known by the trade name Leukine, may be useful to provide relief to patients suffering from an often debilitating form of inflammatory bowel disease, Crohn’s disease.
This finding was reported in the May 26 issue of The New England Journal of Medicine by researchers from Harvard Medical School, the University of Florida and Washington University School of Medicine who led a national multicenter study of the drug sargramostim.
The best way to treat Crohn’s disease is immune system stimulation, and not immune system suppression, according to Dr. John F. Valentine, an associate professor of gastroenterology, Hepatology and nutrition at UF’s College of Medicine and the Malcom Randall Veterans Affairs Medical Center.
According to a report by researchers in an issue of The New England Journal of Medicine, nearly half of the patients with a debilitating form of inflammatory bowel disease experienced disappearance of their symptoms within 6 weeks of initiating a medication that was usually reserved for patients afflicted with cancer.
Researchers from Harvard Medical School, the University of Florida, and Washington University School of Medicineassisted in leading the national multicenter study of the drug sargramostim, which is also known by the trade name Leukine.
John F. Valentine, M.D., an associate professor of gastroenterology, hepatology and nutrition at UF’s College of Medicine and the Malcom Randall Veterans Affairs Medical Center, said that these findings would lead to a renewed debate over the cause and best treatment option for Crohn’s disease.
A prospective new treatment approach has been uncovered by researchers to treat severe asthma by blocking a powerful immune system chemical that is present in large quantities in patients, according to a small study in Thorax.
Severe asthma though rare can be noticed in around one in every ten asthmatics and progressively higher doses of steroids are required to be administered in an attempt to control symptoms.
The research team investigated tumor necrosis factor alpha (TNF alpha) that is found in many chronic inflammatory conditions such as rheumatoidarthritis, Crohn’s disease, and psoriasis.
As much as half the patients suffering from an often debilitating form of inflammatory bowel disease can experience their symptoms starting to disappear in as short as just six weeks by initiating use of a medicine generally reserved for cancer patients, researchers reported in the May 26 issue of The New England Journal of Medicine.
Researchers from Harvard Medical School, the University of Florida and Washington University School of Medicine provided assistance to lead this national multicenter study of the drug sargramostim, which is also known by the trade name Leukine.
Dr. John F. Valentine, an associate professor of gastroenterology, hepatology and nutrition at UF’s College of Medicine and the Malcom Randall Veterans Affairs Medical Center, said these findings can lead to renewed debate over cause of Crohn’s disease and the best method of treating it that actually could be immune system stimulation, and not immune system suppression.
The University of Nottingham researchers recently launched a major clinical trial to identify the role of stem cells for “rebooting” the immune system and offering a cure for Crohn’s disease.
The researchers aimed at finding if the stem cells obtained from a patient’s body could be used for providing effective, long-term remissions for tens of thousands of people.
The stem cell study into Crohn’s Disease at The University of Nottingham is funded by the Broad Medical Research Program of The Eli and Edythe Broad Foundation, a philanthropic organization based in California.
An FDA-approved drug, naltrexone, presently recommended and used for easing symptoms of withdrawal from substance abuse could be an effective option for providing relief to people with Crohn’s disease.
Crohn’s disease is believed to affect nearly 500,000 people in the United States alone.
Jill P. Smith, a gastroenterology specialist and researcher at the College of Medicine and Penn State Milton S. Hershey Medical Center, presented her findings in Los Angeles at the National Association of Gastroenterologists annual Digestive Diseases Week conference.
The role of stem cells in rebooting the immune system and providing a treatment option is under the scanner by researchers from University of Nottingham launching a major clinical trial to confirm the same.
The involved researchers are examining if the stem cells obtained from a patient’s body can be used to provide effective remissions in the long run.
This stem cell study into Crohn’s Disease at The University of Nottingham is funded by the Broad Medical Research Program of The Eli and Edythe Broad Foundation, a philanthropic organization based in California.
Drug combination useful for remission in Crohn’s disease
A Mayo Clinic study has suggested that the combination of biologic therapy with immune-suppressing drugs first instead of the drugs alone can be more than just beneficial to prompt remission from Crohn’s disease in a better way.
The therapy involving drug Sargramostim or Leukine could be helpful for managing disease activity and providing significant relief to patients afflicted with Crohn’s disease, which is a debilitating form of inflammatory bowel disease.
Researchers from the 
A therapy involving drug sargramostim, which is also known by the trade name Leukine, may be useful to provide relief to patients suffering from an often debilitating form of inflammatory bowel disease, 
According to a report by researchers in an issue of The New England Journal of Medicine, nearly half of the patients with a debilitating form of inflammatory bowel disease experienced disappearance of their symptoms within 6 weeks of initiating a medication that was usually reserved for patients afflicted with cancer.
A prospective new treatment approach has been uncovered by researchers to treat severe asthma by blocking a powerful immune system chemical that is present in large quantities in patients, according to a small study in Thorax.
As much as half the patients suffering from an often debilitating form of inflammatory bowel disease can experience their symptoms starting to disappear in as short as just six weeks by initiating use of a medicine generally reserved for cancer patients, researchers reported in the May 26 issue of The New England Journal of Medicine.
An FDA-approved drug, naltrexone, presently recommended and used for easing symptoms of withdrawal from substance abuse could be an effective option for providing relief to people with Crohn’s disease.
The role of stem cells in rebooting the immune system and providing a treatment option is under the scanner by researchers from